Outcomes of Allogeneic Stem Cell Transplant (allo-SCT) Recipients in the Era of Newer Antifungal Agents

Fungal infections (FI) are a leading cause of morbidity and mortality among patients undergoing allo-SCT. The newer anti-fungal agents, the echinocandins and extended spectrum azoles, have offered alternatives to Amphotericin B and fluconazole. Data from large patient samples evaluating the magnitude of benefit with the newer anti-fungal agents are lacking.

Objective

We analyzed the Nationwide Inpt Sample (NIS) database from Healthcare Cost and Utilization project to evaluate the trends in the incidence of FI and to evaluate the potential impact of newer anti-fungal agents on in-hospital mortality (IHM) among allo-SCT recipients.